Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method - 29/11/23
![](/templates/common/images/mail.png)
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Objective |
To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes.
Material and methods |
The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
Results |
Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3–T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.
Conclusion |
Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.
Le texte complet de cet article est disponible en PDF.Keywords : Salivary gland cancer, Radiotherapy, Hadrontherapy
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?